In the news · Updated October 28, 2026
Headlines, with the context left in.
What changed, what was actually studied, and what a headline does not establish.
October 28, 2026 · Sponsor-reported trial results
Retatrutide: what "double the weight loss" refers to.
ABC News reported new Lilly results comparing investigational retatrutide with Ozempic. Lilly's primary release describes TRANSCEND-T2D-2: a randomized, open-label phase 3 trial in 1,298 adults with type 2 diabetes over 80 weeks.
The sponsor reported average weight changes of 19.5% and 20.9% in the two retatrutide groups, compared with 9.4% for Ozempic 2 mg. These are the release's efficacy-estimand results, assuming participants stayed on treatment without added blood-sugar medicines. They are not an outcome promised to every patient.
Gastrointestinal adverse events were common. Treatment discontinuation due to adverse events was 4.8% and 7.9% in the retatrutide groups versus 2.7% in the comparison group.
What this does not mean
Lilly says retatrutide remains investigational and is not FDA-approved. Detailed results are planned for a medical meeting and peer-reviewed publication. The trial does not test ClearCost products, all people seeking weight loss, or an online vial with a similar name. We have not relabeled GLP-1, GLP-2 or GLP-3 catalog entries as retatrutide.
Read the supplied ABC article ↗ · Read Lilly's primary announcement ↗
October 28, 2026 · HHS policy announcement
Six peptides and a conditional compounding policy.
HHS posted an interim enforcement-discretion policy covering BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 in specified forms and routes. It describes circumstances in which HHS does not intend to take action against qualifying state-licensed pharmacies, federal facilities or licensed physicians compounding under section 503A.
The route is patient-specific prescription compounding, not unrestricted retail sale. Conditions include qualified manufacturing, lot-level testing, reporting and a single active ingredient. Labeling must say: "This is a compounded drug product. Not for resale."
Status matters
The public-inspection notice calls the policy a draft and schedules Federal Register publication for October 30, with a two-week comment period. The policy uses present-tense enforcement language, but we have not verified a separate effective-date clause. It does not grant FDA approval or make every product bearing one of these names eligible.
This announcement does not establish that ClearCost's current supply or dropship model meets the conditions. Blends such as BPC-157 + TB-500 are not covered by its single-active-ingredient condition. Ordering and payments remain off.
Read the HHS policy and appendices ↗ · Check the Federal Register status ↗
Our editorial rule.
We link the original source, name the evidence type and date, and separate findings from product claims. News is not a diagnosis, treatment recommendation or product clearance. This page is a curated update, not a live news feed.
Read studies & science → · Full upcoming menu →